Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
about
Modern Technologies for Creating Synthetic Antibodies for Clinical application.Developing bifunctional beta-lactamase molecules with built-in target-recognizing module for prodrug therapy: identification of Enterobacter Cloacae P99 cephalosporinase loops suitable for randomization and phage-display selection.A modular IgG-scFv bispecific antibody topology.Therapy of murine pulmonary aspergillosis with antibody-alliinase conjugates and alliin.Synthesis, biological evaluation, and live cell imaging of novel fluorescent duocarmycin analogs.Optical imaging of targeted β-galactosidase in brain tumors to detect EGFR levelsDesign of a VLP-nanovehicle for CYP450 enzymatic activity delivery.Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity.CNOB/ChrR6, a new prodrug enzyme cancer chemotherapyThe Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics.Antibody-enzyme fusion proteins for cancer therapy.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.Self-immolative spacers: kinetic aspects, structure-property relationships, and applications.Advances in oral delivery of anti-cancer prodrugs.Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy.The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.Antibody-induced oligomerization and activation of an engineered reporter enzyme.Enzyme Prodrug Therapy Engineered into Electrospun Fibers with Embedded Liposomes for Controlled, Localized Synthesis of Therapeutics.Investigation of the transformations of a novel anti-cancer agent combining HPLC, HPLC-MS and direct ESI-HRMS analyses.The two faces of potent antitumor duocarmycin-based drugs: a structural dissection reveals disparate motifs for DNA versus aldehyde dehydrogenase 1 affinity.Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy.
P2860
Q30467308-22E60571-C78C-4F18-8C83-E39B8C61157EQ33444939-E99305F0-1B83-4370-B020-8969BD9D2DE7Q33519465-54C2E29C-C7A5-4B01-B1A4-907281C19524Q33613647-836E7CE3-6B4E-4341-9AEB-289E649DD285Q34480712-227B079B-A6B3-4F59-A467-7C7B631442FAQ35624259-89121FEA-DFA9-42B9-8041-E6D4C9A805C4Q36142345-59251BF4-10D2-425F-B85B-1A68B23A7B36Q36399908-9C70584D-C022-477B-8950-BCDF2B2270C4Q37163327-6E330870-79BF-475D-97C7-8E382903F85CQ37217739-AB45D650-CF62-4FF6-903B-575BDDA34B03Q37638585-F1BB7D86-F3B6-4634-A867-64DAB3C50F5EQ37842324-3C79AADD-AF62-4886-ABFF-13A20DE27358Q38072598-981D7B96-6852-4B40-B832-9A36BC7F0417Q38177279-34146AC6-BB84-4E01-BAAC-4AF4FEDFD8B3Q38520280-A79D55C7-3514-4A94-B7B0-CA228E03B6D0Q38862820-9313E2EB-F83A-481E-A10D-3B34C22A4F9EQ38979784-29AE58CD-96F3-47A5-A44C-1AD38CAA45B3Q39229406-4FC329C5-6C47-4676-B91D-775444C614DDQ39274501-BBDCF9FC-9450-4AC0-B547-B5FBBE3320A4Q41327219-77921C97-B0ED-467E-8EA1-290D3BF33A6DQ41502443-6A7FC301-FAE8-4810-9A36-42A3C7D2054EQ42215830-2009A882-C0F0-4E6F-A44F-45707E70DED2Q50987490-D56E09CE-A7DD-4CF0-B9F4-0AE4E9E01EBCQ52688892-25860D93-054B-4B0B-AF3A-78C711CFF9B7
P2860
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
@ast
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
@en
Antibody-directed enzyme prodrug therapy
@nl
type
label
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
@ast
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
@en
Antibody-directed enzyme prodrug therapy
@nl
prefLabel
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
@ast
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
@en
Antibody-directed enzyme prodrug therapy
@nl
P2860
P1476
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
@en
P2093
Kenneth D Bagshawe
P2860
P304
P356
10.1586/14737140.6.10.1421
P577
2006-10-01T00:00:00Z